In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Paragon 28 (FNA – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $9.50.
According to TipRanks, O’Brien is a 4-star analyst with an average return of 6.0% and a 51.53% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Penumbra, Alphatec Holdings, and Boston Scientific.
Currently, the analyst consensus on Paragon 28 is a Strong Buy with an average price target of $16.20, a 70.53% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $20.00 price target.
FNA market cap is currently $787M and has a P/E ratio of -16.33.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FNA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Paragon 28 (FNA) Company Description:
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot.
Read More on FNA:
